;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=22961666;
RX   PubMed=23381221;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24135919;
RX   PubMed=24279929;
RX   PubMed=24465237;
RX   PubMed=24670534;
RX   PubMed=25120651;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=28408844;
RX   PubMed=29444439;
RX   PubMed=29681454;
RX   PubMed=30038707;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=31978347;
RX   PubMed=33425914;
RX   PubMed=35839778;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=12
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/n/cell-lines-detail-613.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Population: Caucasian.
CC   Characteristics: Expresses HPRT1 at the surface of the cell membrane (PubMed=28408844).
CC   Doubling time: 33 hours (Note=In RPMI 1640 + 10% FBS), 60 hours (Note=In ACL-3), 42 hours (Note=In ACL-3 + BSA) (PubMed=3940644); 19 hours (PubMed=7718330); 0.8 days (PubMed=11551417); 21.5 hours (PubMed=29681454); 18.39 +- 1.35 hours (PubMed=33425914); ~23 hours (DSMZ=ACC-737); 17.8 hours (NCI-DTP=NCI-H460).
CC   HLA typing: A*24,68; B*35,51; C*03,15; DQB1*03:01:01,05:01:01; DRB1*01,04 (PubMed=15748285).
CC   HLA typing: A*24:02,68:01; B*35:01,51:01; C*03:03,15:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (PubMed=12068308; PubMed=12794755; PubMed=17088437; DepMap=ACH-000463).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; HGNC:11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=1311061; PubMed=15900046; PubMed=20557307).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.96%; East Asian, South=0%; South Asian=0.15%; European, North=65.65%; European, South=32.24% (PubMed=30894373).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): AddexBio=C0016003/39; ATCC=HTB-177; CCRID; Cosmic-CLP=905943; DSMZ=ACC-737; KCLB=30177; PubMed=19372543; PubMed=25877200; PubMed=33425914; Technion Genomics Center
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D10S1248: 13
ST   D12S391: 21
ST   D13S317: 13
ST   D16S539: 9
ST   D18S51: 13,15
ST   D19S433: 14
ST   D1S1656: 11,14.3
ST   D21S11: 30
ST   D22S1045: 17
ST   D2S1338: 17,25
ST   D2S441: 11,11.3
ST   D3S1358: 15,18
ST   D5S818: 9,10
ST   D7S820: 9,12
ST   D8S1179: 12
ST   DYS391: 11
ST   FGA: 21,23
ST   Penta D: 11,13
ST   Penta E: 5
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 50
//
47:4068-4085(2019).
//

RT   modeling.";
RL   Stem Cell Res. 23:73-76(2017).
//
6-4;
RA   Kaiser-McCaw Hecht B., Epstein A.L., Berger C.S., Kaplan H.S.,
RA   Hecht F.;
RT   "Histiocytic lymphoma cell lines: immunologic and cytogenetic
RT   studies.";
RL   Cancer Genet. Cytogenet. 14:205-218(1985).
//
ins D.W., Brinckerhoff C.E.;
RT   "Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to
RT   PLX4032.";
RL   Pigment Cell Melanoma Res. 27:495-501(2014).
//
vanced stages of oral
RT   squamous cell carcinoma.";
RL   Cancer Sci. 97:1351-1358(2006).
//
  Cell Stem Cell 8:357-359(2011).
//
87; DOI=10.1038/nature09671; PMCID=PMC5024568;
RA   Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H.,
RA   Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. 3rd,
RA   Romesser P.B., Wright G., Powell J.I., Rosenwald A.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D.,
RA   Chan W.-C., Staudt L.M.;
RT   "Oncogenically active MYD88 mutations in human lymphoma.";
RL   Nature 470:115-119(2011).
//
ystemic chemotherapy of murine bladder cancer.";
RL   Cancer Res. 37:2918-2929(1977).
//
p.1840180216;
RA   Yano H., Iemura A., Fukuda K., Mizoguchi A., Haramaki M., Kojiro M.;
RT   "Establishment of two distinct human hepatocellular carcinoma cell
RT   lines from a single nodule showing clonal dedifferentiation of cancer
RT   cells.";
RL   Hepatology 18:320-327(1993).
//
tor detected
RT   by a monoclonal antibody.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7888-7892(1986).
//
, Mirakhori M., Roozafzoon R., Rajabi M.T.,
RA   Tabatabaie S.Z., Farzanfar F., Khoshzaban A., Asadi-Amoli F.;
RT   "Isolation and characterization of a new cell line of
RT   retinoblastoma.";
RL   PeerJ PrePrints 5:e2780v1-e2780v1(2017).
//
0.1038/nature05329; PMCID=PMC2669898;
RA   Redon R., Ishikawa S., Fitch K.R., Feuk L., Perry G.H., Andrews T.D.,
RA   Fiegler H., Shapero M.H., Carson A.R., Chen W.-W., Cho E.K., Dallaire S.,
RA   Freeman J.L., Gonzalez J.R., Gratacos M., Huang J., Kalaitzopoulos D.,
RA   Komura D., MacDonald J.R., Marshall C.R., Mei R., Montgomery L.,
RA   Nishimura K., Okamura K., Shen F., Somerville M.J., Tchinda J.,
RA   Valsesia A., Woodwark C., Yang F.-T., Zhang J.-J., Zerjal T., Zhang J.,
RA   Armengol L., Conrad D.F., Estivill X., Tyler-Smith C., Carter N.P.,
RA   Aburatani H., Lee C., Jones K.W., Scherer S.W., Hurles M.E.;
RT   "Global variation in copy number in the human genome.";
RL   Nature 444:444-454(2006).
//
azquez E.J., Weber K.S.,
RA   Robison R.A., O'Neill K.L.;
RT   "Non-small-cell lung cancer cell lines A549 and NCI-H460 express
RT   hypoxanthine guanine phosphoribosyltransferase on the plasma
RT   membrane.";
RL   Onco Targets Ther. 10:1921-1932(2017).
//
occuni P., Di Noto R., Del Vecchio L., Salvatore F., Rotoli B.;
RT   "Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+)
RT   and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+)
RT   lymphoma/leukemia.";
RL   Haematologica 85:496-501(2000).
//

RT   ovary cell.";
RL   Somatic Cell Genet. 9:165-173(1983).
//
E., Maiorana L., Vasta V., Pezzino F.M., Sunkara S., Wynne K.,
RA   Elia G., Marincola F.M., McCubrey J.A., Libra M., Travali S., Kane M.;
RT   "Characterization of human melanoma cell lines and melanocytes by
RT   proteome analysis.";
RL   Cell Cycle 10:2924-2936(2011).
//
  "Normal human fibroblasts are resistant to RAS-induced senescence.";
RL   Mol. Cell. Biol. 24:2842-2852(2004).
//
col. 28:461-464(1991).
//
RT   bead-based isolation and characterization of its CD90/CD44
RT   subpopulations.";
RL   Oncotarget 8:66254-66269(2017).
//
sner A., Musunuru K., Kathiresan S.,
RA   Daheron L., Zhu J., Gerszten R.E., Deo R.C., Vasan R.S.,
RA   O'Donnell C.J., Cowan C.A.;
RT   "Induced pluripotent stem cell differentiation enables functional
RT   validation of GWAS variants in metabolic disease.";
RL   Cell Stem Cell 20:547-557.e7(2017).
//
0/15384101.2017.1371880; PMCID=PMC5638364;
RA   Moraleva A., Magoulas C., Polzikov M.A., Hacot S., Mertani H.C.,
RA   Diaz J.-J., Zatsepina O.V.;
RT   "Involvement of the specific nucleolar protein SURF6 in regulation of
RT   proliferation and ribosome biogenesis in mouse NIH/3T3 fibroblasts.";
RL   Cell Cycle 16:1979-1991(2017).
//
371/journal.pone.0008067; PMCID=PMC2780725;
RA   Takahashi K., Narita M., Yokura M., Ichisaka T., Yamanaka S.;
RT   "Human induced pluripotent stem cells on autologous feeders.";
RL   PLoS ONE 4:E8067-E8067(2009).
//
hatic vessel endothelial hyaluronan receptor 1.";
RL   Cancer Sci. 109:3171-3182(2018).
//
ussell E., Johnson B., Buchhagen D.L., Bodner S.M., Phelps R.M.,
RA   Gazdar A.F., Minna J.D.;
RT   "High frequency of somatically acquired p53 mutations in small-cell
RT   lung cancer cell lines and tumors.";
RL   Oncogene 7:339-346(1992).
//
Med=9817906; DOI=10.1128/jcm.36.12.3718-3720.1998; PMCID=PMC105273;
RA   Schultz-Cherry S., Dybdahl-Sissoko N., McGregor M., Hinshaw V.S.;
RT   "Mink lung epithelial cells: unique cell line that supports influenza
RT   A and B virus replication.";
RL   J. Clin. Microbiol. 36:3718-3720(1998).
//
.,
RA   Osborne B.;
RT   "Characterization of a mutant T-cell hybridoma line with defects in
RT   the TCR-mediated apoptotic pathway.";
RL   Cell Death Differ. 6:36-47(1999).
//
., Brown A.M., Wellner R.B., Baum B.J.;
RT   "Characteristics of alpha 1-adrenergic receptors in a rat salivary
RT   cell line, RSMT-A5.";
RL   Gen. Pharmacol. 20:175-181(1989).
//
omi M., Goto S.;
RT   "Correction to: Aurora B kinase as a therapeutic target in acute
RT   lymphoblastic leukemia.";
RL   Cancer Chemother. Pharmacol. 88:1055-1056(2021).
//